New Six-year Ocrevus (Ocrelizumab) Data Showed That Earlier Initiation and Continuation of Treatment Reduced...
Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair after...
Two New Drugs Now Available to Treat SPMS
The FDA-approved medications offer additional treatment options for people living with active secondary progressive multiple sclerosis (SPMS).
Until the last few months, the vast majority...
Novartis Announces FDA and EMA Filing Acceptance of Siponimod for Secondary Progressive Multiple Sclerosis...
Novartis announced this week that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company's New Drug...
New drug target for remyelination in MS is identified by UB researchers
Photo: Myelin (green) production by transplanted human oligodendrocyte progenitors cells (red) is greatly improved following the genetic block of M3R expression. (Credit: Jesslie J....
Developing Next Gen Multiple Sclerosis Therapies: Part 5
The following is part of a MStranslate exclusive series which highlights the struggles and obstacles in developing the next generation of therapies and drugs...
My Taking My Life Back Bucket List
I have been living with Primary Progressive Multiple Sclerosis Active (PPMS active) for 40 years, since I was 8 years old. PPMS active is...
Rare Event for PPMS Patients Hosted by Ocrevus Manufacturer
PPMS (Primary Progressive Multiple Sclerosis) patients rarely find local patient education events geared toward them. Since the FDA (USA) approved the first treatment effective...
Novartis multiple sclerosis drug Gilenya shows siginificant effect against pediatric MS in phase III...
Novartis MS Drug Gilenya shows siginificant effect in phase III trial: Against Pediatric MSNovartis’ multiple sclerosis (MS) drug Gilenya (fingolimod) has demonstrated significant effect...
